A detailed history of Keating Investment Counselors Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Keating Investment Counselors Inc holds 2,110 shares of ABBV stock, worth $408,327. This represents 0.16% of its overall portfolio holdings.

Number of Shares
2,110
Previous 5,290 60.11%
Holding current value
$408,327
Previous $963,000 62.51%
% of portfolio
0.16%
Previous 0.4%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$154.79 - $180.76 $492,232 - $574,816
-3,180 Reduced 60.11%
2,110 $361,000
Q1 2024

May 07, 2024

SELL
$159.82 - $182.1 $621,380 - $708,004
-3,888 Reduced 42.36%
5,290 $963,000
Q3 2023

Oct 25, 2023

BUY
$133.59 - $154.65 $410,121 - $474,775
3,070 Added 50.26%
9,178 $1.37 Million
Q1 2023

May 04, 2023

SELL
$144.61 - $166.54 $368,755 - $424,677
-2,550 Reduced 29.45%
6,108 $973,000
Q4 2022

Feb 08, 2023

BUY
$138.31 - $165.87 $1.2 Million - $1.44 Million
8,658 New
8,658 $1.4 Million
Q2 2022

Aug 03, 2022

SELL
$137.62 - $174.96 $305,516 - $388,411
-2,220 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$80.49 - $108.67 $178,687 - $241,247
2,220 New
2,220 $238,000
Q3 2020

Oct 23, 2020

SELL
$85.91 - $100.83 $190,720 - $223,842
-2,220 Closed
0 $0
Q2 2020

Jul 22, 2020

BUY
$73.37 - $98.18 $162,881 - $217,959
2,220 New
2,220 $218,000
Q1 2019

Apr 22, 2019

SELL
$77.14 - $90.79 $172,793 - $203,369
-2,240 Closed
0 $0
Q3 2018

Oct 30, 2018

SELL
$88.91 - $98.84 $102,246 - $113,666
-1,150 Reduced 33.92%
2,240 $212,000
Q2 2018

Aug 01, 2018

SELL
$89.78 - $106.23 $160,257 - $189,620
-1,785 Reduced 34.49%
3,390 $314,000
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $128,814 - $172,494
-1,400 Reduced 21.29%
5,175 $490,000
Q2 2017

Aug 10, 2017

BUY
N/A
6,575
6,575 $477,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Keating Investment Counselors Inc Portfolio

Follow Keating Investment Counselors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keating Investment Counselors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Keating Investment Counselors Inc with notifications on news.